NT 503

Drug Profile

NT 503

Alternative Names: Encapsulated VEGF inhibitor - Neurotech; NT-503; NT-503-2; NT-503-3; Wet AMD encapsulated cell therapy - Neurotech

Latest Information Update: 14 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Neurotech USA
  • Class Cell therapies; Eye disorder therapies
  • Mechanism of Action Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Choroidal neovascularisation

Most Recent Events

  • 14 Jun 2018 Discontinued - Phase-II for Choroidal neovascularisation (Recurrent, Treatment-experienced) in Israel (Intraocular) (Neurotech USA pipeline, June 2018)
  • 14 Jun 2018 Discontinued - Phase-II for Choroidal neovascularisation (Recurrent, Treatment-experienced) in USA (Intraocular) (Neurotech USA pipeline, June 2018)
  • 18 Oct 2016 Neurotech USA terminates phase II portion of a phase I/II trial in Choroidal neovascularisation (Recurrent, Treatment-experienced) in USA and Israel (Neurotech USA pipeline, July 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top